JFJason L. Freedman

Jason L. Freedman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jason L. Freedman has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Mucositis and Pain in the Peri-HSCT Period

    by Arun Gurunathan, Neil S. Patel, Jason L. Freedman


  • Acute Graft-Versus-Host Disease: Diagnosis, Prophylaxis, and Treatment

    by Karen L. Bride, Neil S. Patel, Jason L. Freedman

  • Nutrition in the Peri-HSCT Period

    by Arun Gurunathan, Judy Bailer, Jason L. Freedman

  • List of Contributors

    by Hisham Abdel-Azim, Suchitra S. Acharya, Anurag K. Agrawal, Robert J. Arceci, Mark P. Atlas, Rochelle Bagatell, Nicholas Bernthal, Teena Bhatla, Lionel Blanc, Mary Ann Bonilla, et al.

  • Atypical Chronic Myeloid Leukemia in Two Pediatric Patients

    by Jason L. Freedman, Ami V. Desai, L. Charles Bailey, Richard Aplenc, Bettina Burnworth, Barbara K. Zehentner, David T. Teachey, Gerald Wertheim

    Atypical chronic myeloid leukemia, BCR-ABL1-negative, (aCML) is a rare myeloid neoplasm. Recent adult data suggest the leukemic cells in a subset of patients are dependent on JAK/STAT signaling and harbor CSF3R-activating mutations. We hypothesized that, similar to adult patients, the presence of CSF3R-activating mutations would be clinically relevant in pediatric myeloid neoplasms as patients would be sensitive to the JAK inhibitor, ruxolitinib. We report two cases of morphologically similar pediatric aCML, BCR-ABL1-negative based on WHO 2008 criteria. One patient had CSF3R-activating mutation (T618I) and demonstrated a robust response to ruxolitinib, which was used to bridge to a successful stem cell transplant. The other patient did not have a CSF3R-activating mutation and succumbed to refractory disease CSF3R sequencing analysis for myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Pediatr Blood Cancer


  • Quality Improvement Initiative to Increase Influenza Vaccination in Pediatric Cancer Patients

    by Jason L. Freedman, Anne F. Reilly, Stephanie C. Powell, L. Charles Bailey

    BACKGROUND: Pediatric patients with cancer face more severe complications of influenza than healthy children. Although Centers for Disease Control and Prevention guidelines recommend yearly vaccination in these patients, in our large academic center, METHODS: Eligible patients were >6 months old, within 1 year of receiving chemotherapy, >100 days from stem cell transplant, and had ≥1 outpatient oncology visit between September 1, 2012, and March 31, 2013. Five interventions were instituted concomitantly: (1) family education: influenza/vaccine handouts were provided to families in clinic waiting rooms; (2) health informatics: daily lists of outpatients due for immunization were generated from the electronic medical record and sent automatically to triage staff and nurses; (3) outpatient clinic: patients due for vaccination were given colored wristbands during triage to alert providers; (4) inpatient: vaccine order was built into admission order set; and (5) provider education: staff education was provided at conferences on screening of patients, vaccine ordering, and documentation of refusals/contraindications. RESULTS: The complete influenza immunization rate increased by 20.1% to 64.5%, and the proportion of patients receiving ≥1 dose of vaccination increased by 22.9% to 77.7%. Similar changes were noted across all cancer types, with highest rates of immunization in leukemia/lymphoma patients (86.8%) and lowest in patients after stem cell transplant (66.7%). CONCLUSIONS: Technology, education, and multidisciplinary clinical process changes increased influenza vaccination rates. Ongoing efforts are targeting subgroups with lowest rates of immunization.


  • Predictors of antiemetic alteration in pediatric acute myeloid leukemia

    by Jason L. Freedman, Jennifer Faerber, Tammy I. Kang, Dingwei Dai, Brian T. Fisher, Yuan-Shung Huang, Yimei Li, Richard Aplenc, Chris Feudtner

    Background Better knowledge of patient and cancer treatment factors associated with nausea/vomiting (NV) in pediatric oncology patients could enhance prophylaxis. We aimed to describe such factors in children receiving treatment for acute myeloid leukemia (AML). Methods Retrospective longitudinal cohort study of 1,668 hospitalized children undergoing treatment for AML from the Pediatric Health Information System database (39 hospitals, 1999–2010). Antiemetic alteration, which included switch (a change in prescribed 5‐HT3 receptor antagonists) and rescue (receipt of an adjunct antiemetic), were first validated and then used as surrogates of problematic NV. Logistic and negative binomial regression modeling were used to test whether patient characteristics were associated with problematic NV. Results Increasing age is associated with greater odds of experiencing antiemetic switch and higher relative rate of antiemetic rescue. Within a treatment cycle, each consecutive inpatient chemotherapy day decreased the likelihood of requiring antiemetic alteration. Each consecutive inpatient‐day post‐chemotherapy was associated with decreased need for switch, but increased need for rescue. Subsequent cycles of AML therapy were associated with lower odds of antiemetic switch on both chemotherapy and non‐chemotherapy days, a lower rate of antiemetic rescue on chemotherapy days, and an increased rate of rescue on non‐chemotherapy days. Conclusion In pediatric patients with AML, increasing age is strongly associated with greater antiemetic alteration. Antiemetic alteration occurs early in treatment overall, and early within each admission. While additional cycles of therapy are associated with less alteration overall, there is persistent rescue in the days after chemotherapy, suggesting additional etiologies of NV in pediatric cancer patients. Pediatr Blood Cancer 2014; 61:1798–1805.